$72.2M
BlackRock joined the Series C round alongside existing investors to bring total financing to $100m.
"Exscientia is breaking ground in small molecule drug design, with a platform that radically improves drug discovery"
Evotec
CorporateEvotec operates as a drug discovery alliance and development partnership company with worldwide operations.
Portfolio
1
companies
Portfolio companies
Recent investments
£49.0M
Novo Holdings led the financing round to support portfolio expansion and international growth.
"Through its impressive track record to date, Exscientia has demonstrated the value of combining deep scientific expertise with cutting-edge technology capabilities to significantly accelerate drug discovery. Novo Holdings’ investment underscores our interest in supporting technology companies that enable life science research and innovation, and our commitment to this area. We see significant opportunity for the company to further grow its participation in the drug discovery ecosystem and are excited to work with the Exscientia team in realising this vision."
Novo Holdings + 3 others